DOI: 10.1111/bjh.19069 ISSN:
Clinical significance of antinuclear antibodies in primary immune thrombocytopenia
Guillaume Moulis, Nathalie Aladjidi, Bertrand Godeau- Hematology
Summary
There are discrepancies across guidelines about whether the dosage of antinuclear antibodies (ANAs) is of use at the diagnosis of primary immune thrombocytopenia (ITP). This review describes the current knowledge about ANA prevalence in patients with primary ITP, and their potential usefulness as biomarkers for ITP evolution, response to treatments and increased risk of subsequent development of systemic lupus and thrombosis.